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Immunisation is amongst the most cost-
effective public health interventions for
reducing global child morbidity and mor-
tality [1,2]. The global effort to use
vaccination as a public health intervention
began when theWorldHealth Organization
(WHO) launched the Expanded Pro-
gramme on Immunization (EPI) in 1974.
Over the years there have been several
international efforts to increase EPI cover-
age, including Universal Childhood Immu-
nisation [3]; the Global Alliance for Vac-
cines and Immunisation (GAVI) [4];
Millennium Development Goals (MDGs)
[5]; the Global Immunisation Vision and
Strategy (GIVS) [6]; and most recently, the
Global Vaccine Action Plan (GVAP) [7].
These initiatives, coupled with specific
regional efforts such as the WHO African
Region’s EPI strategic plans of action for the
periods 2001–2005 and 2006–2009 [8], and
the Reach Every District (RED) approach
[9], as well as the efforts of national EPIs,
have seen global coverage with three doses
of the diphtheria-tetanus-pertussis vaccine
by 12 months of age (DTP3) rise from 5% in
1974 to 85% in 2010 [10,11]. However,
sub-Saharan Africa reached only 77%
DTP3 coverage in 2010 [10]. Although
DTP3 is an acknowledged indicator of EPI
performance, it is important to understand
other EPI indicators in Africa. Here, we
assess immunisation systems strengthening,
accelerated disease control efforts, and the
introduction of new and underutilised
vaccines across Africa.
Performance of Childhood
Immunisation Programmes in
Africa
Immunisation Systems
Strengthening
Over the past four decades, extraordi-
nary progress has been made in improving
vaccination coverage in Africa (53 coun-
tries). According to WHO and the United
Nations Children’s Fund (UNICEF) cov-
erage estimates, the number of countries
with national DTP3 coverage of at least
80% increased from one (2%) in 1980,
through 22 (42%) in 1990 and 17 (32%) in
2000, to 35 (67%) in 2010 (Figure 1) [10].
While 35 (67%) countries reported 80%
national DTP3 coverage in 2010, only 16
(30%) countries reported at least 80%
DTP3 coverage in 80% of their districts
[10]. The DTP drop-out rate [((DTP1–
DTP3)/DTP1)6100%] is also used for
measuring EPI performance, where a
DTP drop-out of less than 10% is
considered good. Improvement in the
proportion of countries having a DTP
drop-out rate less than 10% was observed
from 1974 till 1990, stagnating between
1990 and 2000, and then significantly
increasing from 28% in 2000 to 60% in
2010 (p=0.0013) [10].
In 2010, one-fifth of African countries
were yet to implement use of auto-disable
syringes as well as adequate safety and waste
disposal measures [10,12]. Cold chain
management in resource-poor settings,
where electricity is non-existent or erratic,
coupled with a lack of adequate trained staff
to administer vaccines present major chal-
lenges in most African countries [13].
Furthermore, of those children who do
receive the vaccines, many receive them late
or at inappropriate timing and likely receive
sub-optimal disease protection [14–16].
Improvements in immunisation spend-
ing in most African countries have pre-
dominantly been due to donor funds. In
2005, 49% (26/53) of countries reported
that at least half of the costs of their routine
vaccines were funded by government [10].
However, of those that established line
items in their national budgets for rountine
vaccines, over a third of them did not fund
them, and those that had drawn financial
plans did not utilise them to the degree
expected [17]. Only 15% (8/53) of African
countries reported on routine vaccines
funded by government in 2010 [10].
The quality of immunisation data in
many African countries is questionable.
Various external evaluations have identi-
fied many inconsistencies in reported data
suggesting that immunisation data moni-
toring remains weak in most African
countries [18–20].
Accelerated Disease Control
Poliomyelitis, measles, yellow fever, and
neonatal tetanus remain at the forefront of
disease control efforts in Africa. By 2010,
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81% (27/33) of the countries at risk for
yellow fever had introduced the vaccina-
tion into their EPI schedules [21], com-
pared to 27% (9/33) in 2000 [10].
Between 2000 and 2002, the number of
African countries endemic with the wild
poliovirus (WPV) decreased from 12 to
two, and new WPV cases declined by 89%
from 1,863 to 208 [17,22]. However,
following the cessation of polio immunisa-
tion for 12 months in the northern
Nigerian state of Kano beginning in
September 2003, WPV was imported into
29 previously polio-free African countries
[23]. Religious and political leaders urged
parents not to immunise their children as
they believed the vaccine was contaminat-
ed with anti-fertility, HIV, and cancerous
agents [24]. Since 2010, intensified efforts
around the continent have resulted in
WPV cases in Africa dropping by 47%
from 657 in 2010 to 350 in 2011 [25].
Despite these efforts, in 2011, Nigeria
remained endemic, transmission had re-
established in Angola, Chad, and the
Democratic Republic of the Congo
(DRC), and ten other countries reported
importations [26].
While routine measles vaccination had
been established in most African countries
by 1980, low coverage and outbreaks
resulted in the initiation of catch-up and
follow-up supplementary immunisation
activities (SIAs) and case-based surveil-
lance in the 1990s. A total of 24 million
children in seven African countries were
first reached during SIAs between 1996
and 2000 [27]. Between 2000 and 2010,
all except four African countries conduct-
ed at least one catch-up SIA for children
aged 9 months to 15 years, leading to a
92% reduction in measles mortality in sub-
Saharan Africa between 2000 and 2008
[28–30]. Thereafter, due to low measles-
containing vaccine (MCV) coverage and
suboptimal follow-up SIAs, 27 countries
had confirmed measles outbreaks between
2009 and 2011 [31].
In 2000, two-thirds (18/27) of the
countries accounting for 90% of global
neonatal tetanus cases were in Africa [32].
Thereafter, neonatal tetanus elimination
was validated in 20 (38%) African coun-
tries in 2005, increasing to 27 (51%) in
2010 [10].
New and Underutilised Vaccines
There has been significant but slow
progress in the introduction of new and
underutilised vaccines in Africa. HepB and
Hib vaccines were first licensed in the
United States in 1981 and 1985, respec-
tively. By 2005, 20 years later, the
proportion of African countries having
introduced HepB (70%) and Hib (26%)
highlight the need to address underutilisa-
tion of available vaccines on the continent
[10].
Although pneumonia and diarrhoea
remain leading causes of child death
[33], only seven African countries had
introduced the rotavirus and/or pneumo-
coccal conjugate (PCV) vaccines by 2010.
These are ‘‘new vaccines’’ on the market
that are costly and largely unaffordable for
most African countries. Some progress is
anticipated with an additional 16 countries
and nine countries planning to introduce
PCV and rotavirus vaccines, respectively,
by 2013, with GAVI funding [10]. The
Meningitis Vaccine Project (MVP) is a
modern vaccine success story that saw the
development of a new vaccine against
meningococcal group A (the predominant
cause of epidemic meningitis in the
‘‘meningitis belt’’) being developed within
10 years. Negotiations between the MVP
and partners around the world allowed for
the development of this conjugate vaccine
(MenAfriVac) in a low- and middle-
income country (LMIC), India, at a cost
of less than US$0.50/dose [34]. Within 2
years of licensure, six of the 25 countries at
risk have already introduced MenAfriVac
with GAVI support [33].
What Are the Implications for
African Countries?
It is estimated that 1.5 million children
died globally from vaccine-preventable
diseases (VPDs) for which there were
available WHO pre-qualified vaccines in
2010 [35]. Approximately 19.3 million
children did not receive DTP3 worldwide
in 2010, with more than one-third of these
children living in Africa [36]. While Africa
has made remarkable improvements in
immunisation services, this agenda re-
mains largely unfinished with large num-
bers of children remaining unreached,
unvaccinated, under-vaccinated, and still
dying from VPDs. While many countries
have introduced HepB and Hib vaccines,
the majority have not yet introduced PCV
and rotavirus vaccines, and will not have
done so by 2015. This continued failure to
meet agreed targets thus far suggests that
general and country-specific challenges
with regards to immunisation programmes
in Africa have not been fully identified,
understood, and/or addressed effectively
[37].
Paving the Way forward for an
Improved EPI in Africa
With the 2015 deadline for the MDGs
fast approaching [5], it is necessary for
Africa to take stock, critically assess its
position, take ownership of the regional
and country-specific problems, and devel-
op precise strategies to overcome the
challenges identified. The annual cost per
live birth for immunisation in LMICs is
estimated to have increased from an
average of US$6.00 in 2000 to US$25.00
in 2008 (due to HepB and Hib vaccines)
and is likely to increase to US$58.00 if
PCV and rotavirus vaccines are included
[3]. Even with continued support from
donors, political will as well as financial
planning and commitment from African
governments will be key factors for
Summary Points
N There have been significant improvements in the performance of the Expanded
Programme on Immunization (EPI) in Africa since its inception in 1974.
However, there exist wide inter- and intra-country differences.
N Successes such as the introduction of hepatitis B (HepB), Haemophilus
influenzae type B (Hib), and meningococcal group A vaccines across the
continent are milestones indicating growth and development in the right
direction. Conversely polio and measles outbreaks, as well as high vaccine drop-
out rates across the continent, indicate failures within the EPI system that
require evidence-informed corrective interventions.
N With the 2015 deadline for the Millennium Development Goals (MDGs)
approaching, it is necessary for Africa to take stock, critically assess its position,
take ownership of the regional and country-specific problems, and develop
precise strategies to overcome the challenges identified.
N There is need for increased immunisation systems strengthening, as many are
plagued by weak infrastructure and shortage of skilled human resources. More
affordable and adapted vaccines need to be made available.
N Increased political and financial commitments from African governments are
key factors for both maintaining current achievements and making additional
progress for EPI in Africa.
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successful introduction and sustainability
of new vaccines in EPI schedules in Africa.
Issues of immunisation awareness, de-
mand for immunisation, level of trust in
health system, adequate human resources,
access, timeliness of vaccinations, service
delivery, poor infrastructure, and immu-
nisation monitoring are among the many
challenges faced by most African coun-
tries, all requiring evidence-based inter-
ventions [37–39]. Rwashana and col-
leagues from Uganda provide a good
example of understanding the specific
challenges and dynamics faced by an
individual immunisation programme in
the African context [40]. Identification of
suitable and effective interventions to
address identified problems within immu-
nisation programmes is then of great
importance to ensure best use of the
limited resources available [41,42]. Vac-
cine procurement and pricing strategies,
vaccine adaptation to suit LMICs, as well
as the establishment of vaccine production
in LMICs remain essential components of
helping to strengthen immunisation sys-
tems across Africa [13]. The polio boycott
in northern Nigeria highlights the need for
adequate communication about vaccines
across Africa, the consequences of not
urgently addressing concerns about per-
ceived vaccine safety, as well as the need
for prompt high-quality outbreak investi-
gations [22–26].
We believe that in order for Africa to
take advantage of the new decade of
vaccines and extend the full benefits of
immunisation to its citizens by 2020 and
beyond, a critical assessment is a funda-
Figure 1. Colour-coded maps of Africa showing national coverage with the third dose of the diphtheria-tetanus-pertussis vaccine
(DTP3) at the end of each decade since 1974. (Source of data: World Health Organization [10].)
doi:10.1371/journal.pmed.1001405.g001
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mental first step. The recently introduced
GVAP is guided by six principles: country
ownership, shared responsibility and part-
nership, equity, integration, sustainability,
and innovation [7]. While this provides
generalised strategies for attaining outlined
goals, it is absolutely necessary for com-
plementary tailor-made African approach-
es accompanied by robust monitoring and
accountability frameworks.
Conclusion
African countries must be commended
for giant steps made in EPI performance.
However, there exist wide inter- and intra-
country differences, with large numbers of
African children remaining unreached,
unvaccinated, under-vaccinated, and still
dying from VPDs. Immunisation systems
strengthening is essential, as most are
under-staffed with inadequate resources
to function efficiently. Issues of vaccine
supply, financing, and sustainability in
Africa require urgent attention. Increased
political and financial commitment from
governments as well as coordinated na-
tional and continental evidence-informed
efforts by all immunisation stakeholders
are needed to both maintain current
achievements and make additional prog-
ress for EPI in Africa. African leaders must
be held accountable for meeting agreed
country targets and honouring interna-
tional commitments made.
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